IMAC Holdings IncNASDAQ:BACKNASDAQ FSI:E. Delinquent (Issuer missed regulatory filing deadline)
- LAST PRICE1.1900
- TODAY'S CHANGE (%)0.0100 (0.8475%)
- Bid / Lots1.2200/ 4
- Ask / Lots1.2400/ 2
- Open / Previous Close1.2500 / 1.1800
- Day Range
- 52 Week Range
- Volume37,632
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BACK |
|---|---|---|
| 09:48 ET | 100 | 1.25 |
| 10:06 ET | 144 | 1.215 |
| 10:33 ET | 201 | 1.2192 |
| 10:47 ET | 1500 | 1.2 |
| 11:27 ET | 13285 | 1.26 |
| 11:32 ET | 19651 | 1.1401 |
| 11:56 ET | 1500 | 1.19 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
IMAC Holdings Inc | 2.0M | -0.2x | --- |
PTS Inc | 1.9M | --- | --- |
Modern Mobility Aids Inc | 1.2M | -0.2x | --- |
Cyberdyne Inc | 164.4M | -19.6x | --- |
BioCorRx Inc | 3.4M | -0.7x | --- |
Mitesco Inc | 3.4M | -0.8x | --- |
Company Information
IMAC Holdings, Inc. is a clinical research and commercialization company. The Company is focused on innovative medical advancements and care in the oncology, neurological, and orthopedic medical specialties. The Company is focused on providing natural, non-opioid solutions to pain as consumers demand conservative treatments for an aging population. Its Investigational New Drug division conducted a clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson’s disease. The Company is also engaged in providing the precision medicine business. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDTs are utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer.
Contact Information
- Headquarters
- 3401 MALLORY LANE, SUITE 100FRANKLIN, TN, United States 37067
- Phone
- ---
- Fax
- 302-655-5049
Executives
- Chief Executive Officer
- Faith Zaslavsky
- Chief Financial Officer
- Sheri Gardzina
- Director
- Peter Beitsch
- Director
- Matthew Schwartz
- Independent Director
- Maurice Evans
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.31 |
EPS | $-5.04 |
Book Value | $-0.66 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
